AI English summary of an SEC filing — figures as filed

The company said Dr. D. Gary Gilliland notified the Board of Directors on December 5, 2025 of his decision to retire from the Board, effective December 31, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Dec 10, 2025Period of report Dec 5, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

The company said Dr. D. Gary Gilliland notified the Board of Directors on December 5, 2025 of his decision to retire from the Board, effective December 31, 2025.
The company said Dr. Gilliland became a director in 2014 and served on the Audit Committee and Quality and Compliance Committee. In the press release, Adam Schechter, chairman and CEO, cited his tenure as more than 10 years.
The company said Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020, and previously served as Senior Vice President of Merck Research Laboratories and Oncology Franchise Head.
The company said it issued a press release on December 10, 2025 announcing Dr. Gilliland's retirement from the Board. In the press release, lead independent director Dr. Garheng Kong expressed gratitude for his commitment.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Gilliland Director Notifies Board of Retirement; Effective Date

The company said Dr. D. Gary Gilliland notified the Board of Directors on December 5, 2025 of his decision to retire from the Board, effective December 31, 2025.

Source · Based on the filing body and exhibits

Director Tenure and Committee Service

The company said Dr. Gilliland became a director in 2014 and served on the Audit Committee and Quality and Compliance Committee. In the press release, Adam Schechter, chairman and CEO, cited his tenure as more than 10 years.

Source · Based on the filing body and exhibits

Dr. Gilliland's Key Career Positions

The company said Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center since January 2020, and previously served as Senior Vice President of Merck Research Laboratories and Oncology Franchise Head.

Source · Based on the filing body and exhibits

Press Release Issued; Board Statement

The company said it issued a press release on December 10, 2025 announcing Dr. Gilliland's retirement from the Board. In the press release, lead independent director Dr. Garheng Kong expressed gratitude for his commitment.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.